Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
Year: 2015
Type: review
Abstract: PURPOSE: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities. METHODS: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication. RESULTS: A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a plea is made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia. CONCLUSIONS: The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk.
Authors: Jean-Yves Reginster, Cyrus Cooper, René Rizzoli, John A. Kanis, Geoff Appelboom, Ivan Bautmans, Heike A. Bischoff-Ferrari, Maarten Boers, Maria Luisa Brandi, Olivier Bruyère, Antonio Cherubini, Bruno Flamion, Roger A. Fielding, Andrea Ildiko Gasparik, Luc Van Loon, Eugene McCloskey, Bruce H. Mitlak, Alberto Pilotto, Suzanne Reiter-Niesert, Yves Rolland, Yannis Tsouderos, Marjolein Visser, Alfonso J. Cruz-Jentoft
Institutions: University of Liège, University of Oxford, MRC Lifecourse Epidemiology Unit, University of Southampton, University of Geneva, University Hospital of Geneva, University of Sheffield, Columbia University Irving Medical Center, Vrije Universiteit Brussel, University Hospital Zurich, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Florence, Istituto Nazionale di Riposo e Cura per Anziani, University of Namur, Namur Research Institute for Life Sciences, Tufts University, Jean Mayer Human Nutrition Research Center on Aging, Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș, Maastricht University, Eli Lilly (United States), Ente Ospedaliero Ospedali Galliera, Université de Toulouse, Institut de Recherches Internationales Servier (France), Vrije Universiteit Amsterdam, Hospital Universitario Ramón y Cajal
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,490
Funders: U.S. Department of Agriculture, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, Celgene, Dairy Management, Danone, Endocyte, Regeneron Pharmaceuticals, Cytokinetics, National Institute for Health and Care Research, Shire, Astellas Pharma, Servier, Medical Research Council, Medical Research and Materiel Command
OpenAlex ID: W2214973932
